RCC	renal cell carcinoma
mRCC	metastatic RCC
ICIs	immune checkpoint inhibitors
PD1	programmed death receptor 1
PD-L1	PD-ligand 1
NSCLC	non-small cell lung cancer
WHO	World Health Organization
PR	partial response
CR	complete response
PD	disease progression
SPD	sum of products of the two largest perpendicular diameters
irRC	immune-related response criteria
SD	stable disease
RECIST	response evaluation criteria in solid tumors
irRECIST	immune-related RECIST
imRECIST	immune-modified RECIST
iRECIST	immune RECIST
iUPD	unconfirmed PD
iCPD	confirmed PD
TBP	treatment beyond progression
PFS	progression-free survival
OS	overall survival
ORR	overall response rate
CAR	chimeric antigen receptor